Drug Information

Drug General Information
Drug ID
D0Q4AQ
Former ID
DNC010250
Drug Name
6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530516]
Formula
C10H12BrN5
Canonical SMILES
C1CN(CCN1)C2=NC(=CN3C2=NC=C3)Br
InChI
1S/C10H12BrN5/c11-8-7-16-6-3-13-9(16)10(14-8)15-4-1-12-2-5-15/h3,6-7,12H,1-2,4-5H2
InChIKey
XNILOZDQMHSDIZ-UHFFFAOYSA-N
PubChem Compound ID
46228424
Target and Pathway
Target(s) 5-hydroxytryptamine 2C receptor Target Info Inhibitor [530516]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channels
PANTHER Pathway 5HT2 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (q) signalling events
WikiPathways Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.